Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $65.03 USD
Change Today -0.17 / -0.26%
Volume 3.5M
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVA) Snapshot

Open
$65.42
Previous Close
$65.20
Day High
$65.80
Day Low
$64.50
52 Week High
07/28/15 - $72.31
52 Week Low
10/15/14 - $47.36
Market Cap
55.3B
Average Volume 10 Days
5.6M
EPS TTM
--
Shares Outstanding
850.0M
EX-Date
08/18/15
P/E TM
--
Dividend
$1.36
Dividend Yield
2.07%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVA)

teva pharmaceutical-sp adr (TEVA) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $3.3M
Compensation as of Fiscal Year 2014.

teva pharmaceutical-sp adr (TEVA) Key Developments

Teva Pharmaceutical Industries Limited Pays RUB 300,000 Fine for Failure to Execute FAS Determination

Teva Pharmaceutical Industries Limited notified the Federal Antimonopoly Service (FAS Russia) about paying a RUB 300,000 administrative fine for failure to execute a determination issued by the antimonopoly body. In December 2013 the antimonopoly body found that TEVA violated Cause 5 Part 1 Article 10 of the Federal Law "On Protection of Competition" as a result of refusing to conclude a contract with "BIOTEK" CJSC for supplying "Copaxone" medicinal drug without any economic and technological justification and issued a determination to support competition. The Appeal Court and the Cassation Court confirmed legitimacy of the determination. In January 2014 "BIOTEK" CJSC asked TEVA twice to conclude a contact for supplying "Copaxone" but the company refused to enter into the contract. Therefore, TEVA failed to execute FAS determination and was held administratively liable and fined RUB 300,000. TEVA disagreed with the punishment and filed a lawsuit but Moscow Arbitration Court and the 9th Arbitration Appeal Court pronounced legitimacy of FAS determination.

Teva Pharmaceutical Industries Ltd. Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease

Teva Pharmaceutical Industries Ltd. announced that the New Drug Application (NDA) for SD-809 has been accepted by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington disease (HD), a rare and fatal neurodegenerative disorder caused by the progressive breakdown of nerve cells in the brain. The NDA filing is based on positive results from two Phase-III studies, FIRST-HD and ARC-HD. In the placebo-controlled, randomized FIRST-HD study, SD-809 reduced chorea in patients with HD. Positive data from the Phase-III, open-label ARC-HD study demonstrated that patients were able to safely convert from tetrabenazine, currently the only approved HD treatment, to SD-809 overnight with continued control of chorea. SD-809 was granted Orphan Drug Designation for the treatment of HD by the FDA in November 2014 and became part of Teva’s CNS portfolio with the acquisition of Auspex Pharmaceuticals in May 2015. The FDA designates orphan status to drugs and biologics that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. SD-809 (deutetrabenazine) is an investigational, oral, small molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. SD-809 is being developed for the treatment of chorea associated with Huntington disease, a neurodegenerative movement disorder that impacts cognition, behavior, and movements. The FIRST-HD study showed a favorable safety and tolerability profile, including low rates of depression, somnolence, akathisia/restlessness and anxiety. The safety and tolerability experience observed in the ARC-HD study was consistent with the experience observed in the FIRST-HD study. The most commonly reported adverse events in ARC-HD patients were somnolence, fall, and nasopharyngitis.

Rigrodsky & Long Announces Securities Fraud Class Action Lawsuit Against Teva Pharmaceutical Industries Limited

Rigrodsky & Long, P. A announced that a complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the securities of Teva Pharmaceutical Industries Limited between August 1, 2013 and October 29, 2013, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against certain of the Company’s officers. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business operations, financial condition and prospects. Specifically, the Complaint alleges that the defendants failed to disclose that there was significant internal discord between the Board of Directors (“Board”) and Teva’s senior management during the Class Period (and in particular, significant differences between the Chairman of the Board and the Chief Executive Officer (“CEO”)) concerning execution of the Company’s strategies, including implementation of the critical Cost Cutting Program. As aresult of the foregoing, the Company’s stock traded at artificially inflated prices during the Class Period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $65.03 USD -0.17

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TEVA.
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.